Plexium focuses on targeted protein degraders to reinvent the way medicines are discovered.

The company's DELPhe platform, named for DNA-Encoded Library (DEL) phenotypic (Phe) screening, is a unique drug discovery engine designed to identify novel small molecules for multiple indications, including cancer and inflammatory disease indications.

• Industry

  • Biotechnology
  • Health + Tech

• Milestones

  • Lux investment: 2021

• Founders

  • Swamy Vijayan, PhD

  LUX Partners

  • Adam Goulburn

• Latest Tweets

  • Big news today – we closed a $35M financing w/ @Lux_Capital, Pivotal Bioventures, The Column Group, @DCVC and other… https://t.co/jtR1hty52Z@PlexiumTx - 01:19 PM Jan 21st
  • Don’t miss Plexium CEO Kandaswamy Vijayan’s presentation on “Degrading ‘Undruggable’ Proteins with Molecular-Glues”… https://t.co/5laa8f2ZjD@PlexiumTx - 02:01 PM Oct 23rd
  • Plexium CEO Kandaswamy Vijayan to present on “Degrading ‘Undruggable’ Proteins with Molecular-Glues” at the 2nd Tar… https://t.co/FHaec45GbH@PlexiumTx - 04:02 PM Oct 21st